2616 Panoramica delle azioni CStone Pharmaceuticals, un'azienda biofarmaceutica, ricerca, sviluppa e commercializza farmaci immuno-oncologici e di precisione per rispondere alle esigenze mediche insoddisfatte dei pazienti oncologici in Cina e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
CStone Pharmaceuticals Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per CStone Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione HK$2.36 Massimo di 52 settimane HK$2.78 Minimo di 52 settimane HK$0.80 Beta 0.22 Variazione di 1 mese 7.27% Variazione a 3 mesi 20.41% Variazione di 1 anno 46.58% Variazione a 3 anni -60.67% Variazione a 5 anni -77.31% Variazione dall'IPO -81.65%
Notizie e aggiornamenti recenti
CStone Pharmaceuticals Appoints Yip Betty Ho as Independent Non-Executive Director Dec 30
CStone Pharmaceuticals Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody Dec 23
CStone Pharmaceuticals Announces First Patient Enrollment in the Global Multicenter Phase IB Clinical Trial of CS5001 Dec 19
Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load? Dec 12
CStone Pharmaceuticals Presents Latest Clinical Data on CS5001 for Advanced Lymphoma Dec 09
Non-Executive Director recently bought HK$1.9m worth of stock Nov 02 Vedi altri aggiornamenti
CStone Pharmaceuticals Appoints Yip Betty Ho as Independent Non-Executive Director Dec 30
CStone Pharmaceuticals Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody Dec 23
CStone Pharmaceuticals Announces First Patient Enrollment in the Global Multicenter Phase IB Clinical Trial of CS5001 Dec 19
Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load? Dec 12
CStone Pharmaceuticals Presents Latest Clinical Data on CS5001 for Advanced Lymphoma Dec 09
Non-Executive Director recently bought HK$1.9m worth of stock Nov 02
CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK Oct 31
Key Executive recently bought HK$1.5m worth of stock Oct 23
There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise Oct 04
Consensus revenue estimates decrease by 38%, EPS upgraded Aug 28
CStone Pharmaceuticals to Report First Half, 2024 Results on Aug 23, 2024 Aug 12
CStone Pharmaceuticals Announces European Commission Approval of Sugemalimab (Cejemly) as First-Line Treatment for Non-Small Cell Lung Cancer Jul 26
CStone Pharmaceuticals Announces Change of Joint Company Secretary Jun 19
CStone. Pharmaceuticals Announces Presentation of Latest First-In-Human Data for CS5001 (RoR1 ADC) at ASCO 2024 Jun 05
CStone Pharmaceuticals, Annual General Meeting, Jun 18, 2024 May 26
CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website May 24
Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified May 12
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 25
New minor risk - Financial data availability Apr 12
CStone Announces the Availability of RET Inhibitor GAVRETO® (palsetinib) Manufacturing Localization Application by Center for Drug Evalence of China NMPA Apr 09
Forecast to breakeven in 2026 Apr 03
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer Mar 15
Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop Mar 04
Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet Jan 18
Consensus EPS estimates fall by 38% Jan 11
New minor risk - Share price stability Dec 12 CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma Dec 08
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma Oct 31
CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma Oct 25
CEO, Senior VP & Chief Medical Officer recently bought HK$385k worth of stock Oct 12
The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26% Oct 04
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment? Oct 03
First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Sep 27
New major risk - Revenue and earnings growth Sep 04
CStone Pharmaceuticals Announces Receipt of GCP Inspection Notification from the European Medicines Agency Regarding the Marketing Authorization Application Jul 12
CEO, Senior VP & Chief Medical Officer recently bought HK$1.1m worth of stock Jul 10
CStone Pharmaceuticals Presents Results from Phase 3 Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma at ESMO GI 2023 Jul 01
CStone Pharmaceuticals Announces GAVRETO SNDA Approval by China NMPA for First-Line Treatment of Patients with Locally Advanced or Metastatic Ret Fusion-Positive Non-Small Cell Lung Cancer Jun 27
CEO, Senior VP & Chief Medical Officer recently bought HK$676k worth of stock Jun 27
CStone Pharmaceuticals Announces New Data on AYVAKIT (Avapritinib) in Patients with Advanced Gastrointestinal Stromal Tumor at ASCO 2023 Jun 07
CEO, Senior VP & Chief Medical Officer recently bought HK$285k worth of stock Jun 07
CEO, Senior VP & Chief Medical Officer recently bought HK$457k worth of stock May 17
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 27
Forecast to breakeven in 2024 Mar 16
No longer forecast to breakeven Feb 18 CStone Pharmaceuticals has completed a Follow-on Equity Offering in the amount of HKD 392.8784 million. Feb 17
CStone Pharmaceuticals Provides Earning Guidance for the Year Ended December 31, 2022 Feb 04
Cstone Pharmaceuticals Announces Management Changes Jan 19
CStone Pharmaceuticals Announces the NDA Approval of GAVRETO (Pralsetinib) for the Treatment of Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer and Ret-Altered Thyroid Cancer in Taiwan, China Jan 18
CStone Pharmaceuticals Announces Registrational Clinical Trial of Sugemalimab as First-Line Treatment in Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints Jan 03
CStone Pharmaceuticals Announces Results from the Navigator China Bridging Study of AYVAKIT(avapritinib) Published in the Oncologist Dec 29
Cstone Pharmaceuticals Presents Updated Data for Gavreto (Pralsetinib) in Chinese Patients with Ret-Fusion Positive Non-Small Cell Lung Cancer at Esmo Asia Congress 2022 Dec 07
CEO, Senior VP & Chief Medical Officer recently bought HK$2.2m worth of stock Nov 22
Less than half of directors are independent Nov 16
Forecast to breakeven in 2024 Nov 11
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment? Oct 20
National Medical Products Administration of China Accepts and Grants Priority Review to the Supplemental New Drug Application (sNDA) for sugemalimab of CStone Pharmaceuticals Sep 14
CEO, Senior VP & Chief Medical Officer recently bought HK$668k worth of stock Sep 14
CStone Pharmaceuticals Announces Acceptance of Priority Review to the Supplemental New Drug Application for Sugemalimab Sep 13
CStone Pharmaceuticals to Report First Half, 2022 Results on Aug 25, 2022 Aug 16
CStone Pharmaceuticals Presents Updated Results of Registrational Study of Sugemalimab in Patients with Stage III NSCLC at WCLC 2022 Aug 08
CStone Pharmaceuticals Announces Executive Changes Jul 29
Hong Kong, China Approve GAVRETO of CStone Pharmaceuticals Jul 16
CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China Jul 15
Forecast to breakeven in 2024 Jul 13
CStone Pharmaceuticals, Annual General Meeting, Jun 30, 2022 Jun 08
CStone Pharmaceuticals Presents Pre-Specified Overall Survival Data of Sugemalimab for First-Line Treatment of Stage Iv Non-Small Cell Lung Cancer At Asco 2022 Jun 07 CStone Pharmaceuticals Presents Updated Results of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma at ASCO 2022
CStone Pharmaceuticals Presents Clinical Results of Sugemalimab in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma Via an Oral Abstract Session At ASCO 2022 Jun 04
Less than half of directors are independent Jun 01
CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC May 17
CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of Tibsovo Apr 22
CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific Antibody-Based Therapeutic Candidate CS2006/NM21-1480 At the American Association for Cancer Research (AACR) Annual Meeting 2022 Apr 13
CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Clinical Trial of Cs5001, A Potential Global Best-In-Class Ror1-Targeting ADC Mar 31
CStone Pharmaceuticals to Report Fiscal Year 2021 Results on Mar 24, 2022 Mar 23
CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China Feb 17
CStone Pharmaceuticals Announced New Drug Approval of China's First Idh1 Inhibitor Tibsovo® (Ivosidenib Tablets) as A New Precision Therapy for Patients with Acute Myeloid Leukemia Feb 09 EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
CStone Pharmaceuticals Announces Two Key Phase 3 Registrational Clinical Trials of Sugemalimab Completed Patient Enrollment Jan 18 Cstone Pharmaceuticals Announces the Registrational Clinical Study Results of Sugemalimab in Stage IV Non-Small Cell Lung Cancer Published in the Lancet Oncology
CStone Announces Phase 2 GEMSTONE-201 Trial Met Primary Endpoint of Objective Response Rate (ORR) in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) Jan 13
CStone Announces IND Approval for the Pivotal Study in China of Lorlatinib for the Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer Jan 05
CStone Pharmaceuticals Announces the IND Approval of CS5001, a Potential Global Best-In-Class ROR1-Targeting ADC by the U.S. Food and Drug Administration Jan 04
CStone Announces New Drug Approval of Precision Therapy AYVAKIT® (Avapritinib) in Hong Kong, China for the Treatment of PDGFRA D842V Mutant Gastrointestinal Stromal Tumors (GIST) Dec 28
CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy Dec 23
Chairman & CEO recently sold HK$10m worth of stock Dec 23
CStone Pharmaceuticals Announces New Drug Approval of Cejemly (Sugemalimab) in China to Potentially Reshape the Landscape of Immuno-Oncology Therapy in Lung Cancer Dec 22
Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt? Dec 17
Cstone Presents Preliminary Results from Phase Ib Study of the Anti-Ctla-4 Monoclonal Antibody (Mab) Cs1002 in Combination with the Anti-Pd-1 Mab Cs1003 in Patients with Advanced Solid Tumors at ESMO 2021 Sep 21
EQRx and its Partner CStone Pharmaceuticals Announce Presentation of Phase 3 Data Demonstrating Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021 Sep 20
CStone Pharmaceuticals Will Present Registrational Clinical Study Data of Sugemalimab in Patients with Stage III Non-Small Cell Lung Cancer in an Oral Presentation At ESMO Congress 2021 Sep 19 CStone Pharmaceuticals Receives China NMPA IND Approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA Multi-Specific Antibody, Marking Further Expansion of Its Pipeline 2.0
CStone Pharmaceuticals Presents Registrational Bridging Study Data for Gavreto (Pralsetinib) Highlighting Efficacy and Safety in Chinese Patients with Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer at Iaslc Wclc 2021 Sep 09 Rendimenti per gli azionisti 2616 HK Biotechs HK Mercato 7D 0.9% 5.8% 2.9% 1Y 46.6% 17.6% 26.3%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 2616 ha superato il Hong Kong Biotechs che ha restituito 17.6 % nell'ultimo anno.
Rendimento vs Mercato: 2616 ha superato il mercato Hong Kong che ha restituito 26.3 % nell'ultimo anno.
Volatilità dei prezzi Is 2616's price volatile compared to industry and market? 2616 volatility 2616 Average Weekly Movement 7.5% Biotechs Industry Average Movement 7.8% Market Average Movement 6.4% 10% most volatile stocks in HK Market 13.8% 10% least volatile stocks in HK Market 3.0%
Prezzo delle azioni stabile: 2616 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Hong Kong.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di 2616 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda CStone Pharmaceuticals, azienda biofarmaceutica, ricerca, sviluppa e commercializza farmaci immuno-oncologici e di precisione per rispondere alle esigenze mediche insoddisfatte dei pazienti oncologici in Cina e a livello internazionale. L'azienda offre Sugemalimab, un anticorpo monoclonale contro il ligando 1 della morte programmata (PD); GAVRETO, un inibitore di RET per il trattamento di pazienti con tumori della tiroide midollari e RET fusion-positivi avanzati o metastatici; e avapritinib, un inibitore di KIT/PDGFRA per il trattamento di adulti con tumori stromali gastrointestinali non resecabili o metastatici portatori di una mutazione dell'esone 18 di PDGFRA. La pipeline di prodotti dell'azienda comprende Nofazinlimab, un anticorpo PD-1 per il trattamento di pazienti con carcinoma epatocellulare, e Ivosidenib, un inibitore dell'isocitrato deidrogenasi 1 (IDH1) per il trattamento di adulti con leucemia mieloide acuta recidivata o refrattaria con mutazione IDH1.
Mostra di più CStone Pharmaceuticals Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di CStone Pharmaceuticals con la sua capitalizzazione di mercato? 2616 statistiche fondamentali Capitalizzazione di mercato HK$3.01b Guadagni(TTM ) -HK$152.10m Ricavi(TTM ) HK$487.94m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 2616 Conto economico (TTM ) Ricavi CN¥456.53m Costo del fatturato CN¥133.65m Profitto lordo CN¥322.89m Altre spese CN¥465.20m Guadagni -CN¥142.31m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.11 Margine lordo 70.73% Margine di profitto netto -31.17% Rapporto debito/patrimonio netto 65.5%
Come si è comportato 2616 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/07 06:52 Prezzo dell'azione a fine giornata 2025/02/07 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche CStone Pharmaceuticals è coperta da 3 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Ziyi Chen Goldman Sachs Ling Wang J.P. Morgan Sean Wu Morgan Stanley
